A. Bush (London, United Kingdom), A. Lindblad (Gothenburg, Sweden)
The role of CFTR/ENaC genotype in cystic fibrosis-like phenotypes
A. Norek, T. Bienvenu, S. Scheinert, E. Kusmierek, E. Chrzescijanska, E. Sapiejka, B. Swierczynska, D. Sands, N. Derichs (Warsaw, Lodz, Gdansk, Bydgoszcz, Poland; Paris, France; Berlin, Germany)
|  |
Novel protein biomarkers of bronchiectasis in children with cystic fibrosis
E. DeBoer, M. Kroehl, B. Wagner, M. Nikrad, E. Katilius, S. Sagel, R. Deterding (Aurora, Boulder, United States Of America)
| |
Temperate bacteriophages of pseudomonas aeruginosa as markers of bacterial adaptation in CF and non-CF bronchiectasis
F. Everest, M. Tariq, A. De Soyza, A. Perry, J. Perry, S. Bourke, S. Cummings, C. Lanyon, D. Smith (Newcastle upon Tyne, United Kingdom)
|  |
Microevolution of pseudomonas aeruginosa in cystic fibrosis lungs
N. Cramer, J. Klockgether, B. Tümmler (Hannover, Germany)
| |
Imaging of the nasal mucosa in patients with cystic fibrosis using optical coherence tomography
U. Oltmanns, K. Palmowski, N. Kahn, R. Eberhardt, S. Wege, M. Wiebel, M. Kreuter, F. Herth, M. Mall (Heidelberg, Germany)
| |
The CF-ABLE score: A 2-year evaluation of a 4-year prognostic tool
J. Meurling, C. McCarthy, C. Gunaratnam, N. G. McElvaney (Dublin, Ireland)
| |
The use of telehealth system in improving adherence to nebulised treatment in children with cystic fibrosis: Benefits and pitfalls
C. Thornton, O. Lamptey, E. Chan (Manchester, United Kingdom)
| |
ABPA syndrome (ABPAs) in CF: FEV1 decline, infectious exacerbations and BMI before and after the year of diagnosis (index year), a case control study
F. De Baets, S. Wanyana, L. De Keyzer, P. Schelstraete, F. Haerynck, M. Thomas, S. Van daele (Ghent, Brussels, Belgium)
| |
Screening colonoscopy in adults with cystic fibrosis
S. Naehrig, R. M. Huber, V. Gülberg, J. Behr (Munich, Germany)
| |
Safety, tolerability and efficacy of intravenous aminophylline in adult patients with pulmonary exacerbations of cystic fibrosis
P. Waddingham, N. Simmonds, D. Bilton (London, United Kingdom)
| |
MRI detects changes in structure and perfusion, and response to therapy in early cystic fibrosis lung disease
M. O. Wielpütz, M. Puderbach, A. Kopp-Schneider, M. Stahl, E. Fritzsching, O. Sommerburg, S. Ley, M. Sumkauskaite, J. Biederer, H. U. Kauczor, M. Eichinger, M. Mall (Heidelberg, Germany)
| |
Cystic fibrosis and physical activity: Is there a significant difference to healthy individuals?
A. Jantzen, M. Opoku-Pare, K. Ruf, H. Hebestreit, A. Möller (Zürich, Switzerland; Würzburg, Germany)
| |
Respiratory muscle endurance training in cystic fibrosis
C. Bieli, S. Selina, I. Demet, J. Andreas, M. Alexander (Zürich, Switzerland)
| |
Time constant of respiratory muscle relaxation in patients with cystic fibrosis
T. Dassios, A. Kaditis, A. Katelari, G. Chrousos, S. Doudounakis, G. Dimitriou (Cambridge, United Kingdom; Athens, Patras, Greece)
| |
Agreement between the lung clearance index and bronchiectasis detected via chest computed tomography in infants and children with cystic fibrosis (CF)
K. Ramsey, T. Rosenow, B. Skoric, A. M. Adams, C. Gallagher, G. Banton, C. Murray, S. Ranganathan, S. Stick, G. Hall (Perth, Melbourne, Australia)
| |
Lung deposition of inhaled colistimethate sodium in cystic fibrosis patients
S. Su, T. Riccobene, C. Scott (Jersey City, United States Of America)
| |
Effects of dornase alfa and hypertonic saline on gas mixing in lung periphery in children with cystic fibrosis
F. Singer, S. Stanojevic, S. Yammine, P. Subbarao, R. Jensen, R. Amin, F. Ratjen, P. Latzin (Zurich, Bern, Basel, Switzerland; Toronto, Canada)
| |